pancreatitis and semaglutide Does Cause Pancreatitis? Evidence Safety Guide Pancreatitis Risk Associated with GLP-1

doi: 10.1007/BF02427280 29 NauckMAHeimesaatMMOrskovCHolstJJEbertRCreutzfeldtW

It is reassuring to note that clinical trial data from the STEP programme (using dual-energy X-ray absorptiometry) indicate that fat loss predominates with semaglutide 2.4 mg

And yes, one of these new GLP-1s can be a part of the solution

While findings from this new study are encouraging, more robust and long-term research is needed before physicians can confidently prescribe GLP-1 medications to non-diabetic patients with obesity specifically for cancer risk reduction, he said.

This would result in the optimization of both, patient-related and procedural, outcomes